Encompass Health (EHC) Could Be 21% Undervalued Following Its Dividend Lift
I'm LongbridgeAI, I can summarize articles.Encompass Health (EHC) raised its quarterly dividend to $0.21 per share, drawing attention despite mixed recent stock performance. Analysis suggests the stock is approximately 21% undervalued, with a fair value estimate of $140.50 compared to its last close of $110.50. This valuation gap is driven by strong long-term demand for inpatient rehabilitation services due to an aging population and bed shortages, though risks include labor shortages impacting margins.
Dividend increase puts Encompass Health in focus
Encompass Health (EHC) has drawn fresh attention after lifting its quarterly dividend to US$0.21 per share, with payment scheduled for October 15, 2026, and an ex dividend date of October 1.
See our latest analysis for Encompass Health.
Despite the dividend headline, Encompass Health’s recent share price return has been mixed, with the stock down over the past week but posting a positive 90 day share price return and strong multi year total shareholder returns that point to momentum built over a longer horizon.
If this dividend move has you thinking about where else income and growth stories could come from in healthcare, it may be worth checking out 41 healthcare AI stocks
Encompass Health now trades at a sizeable discount to both intrinsic estimates and analyst targets, even after the dividend lift. Is this simply market caution about execution and costs, or a valuation gap that stands out?
Most Popular Narrative: 21.4% Undervalued
At a last close of $110.50, the most followed narrative on Encompass Health points to a fair value of $140.50, which implies a sizeable valuation gap based on analyst assumptions and a 7.11% discount rate.
The surge in the 65 plus population and persistent undersupply of inpatient rehabilitation beds are driving high and still unmet demand for Encompass Health's core services, ongoing hospital openings and bed expansions position the company to capture significant incremental patient volume, supporting higher revenue growth for years to come.
Read the complete narrative.
Curious what sits behind that fair value for Encompass Health? The narrative leans on steady revenue expansion, firmer margins, and a future earnings multiple that needs to hold up. The exact mix of growth, profitability and required valuation is all laid out in one place.
Result: Fair Value of $140.50 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Encompass Health narrative also leans on continued demand for new hospitals while facing ongoing labor shortages that could put pressure on costs and margins.
Find out about the key risks to this Encompass Health narrative.
Next Steps
If the mix of risks and rewards around Encompass Health feels finely balanced, now is a good time to review the details yourself and decide how it fits your portfolio. To get a clearer picture of both sides of the story, take a look at the 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond Encompass Health?
Do not stop with Encompass Health. Use the Simply Wall St screener to spot clear opportunities, compare fundamentals quickly, and keep your watchlist stocked with fresh ideas.
- Hunt for potential growth stories at accessible prices by reviewing 20 elite penny stocks with strong financials.
- Focus on quality at a discount by scanning the 52 high quality undervalued stocks.
- Prioritise resilience and capital protection by checking the 82 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Encompass Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free Analysis
